Literature DB >> 16834939

Intrathecal therapy for the management of cancer pain.

Shane E Brogan1.   

Abstract

Inadequately managed cancer pain continues to be a significant problem despite increased awareness, improved knowledge and understanding of pain pathophysiology, and standardized treatment guidelines of this distressing and debilitating symptom complex. Small subsets of patients who are refractory to optimal medical management because of drug toxicity or unsatisfactory analgesia may be candidates for exteriorized or implantable intrathecal drug delivery systems. By delivering opioids and other agents directly to the central nervous system, intrathecal drug administration can offer superior pain relief with less toxicity at a fraction of the systemic dose. With adjuncts such as local anesthetics and clonidine, intrathecal therapy also allows for broader therapeutic options in the most difficult of cases. In general, intrathecal therapy is underused despite evidence of its efficacy, safety, and cost-effectiveness.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16834939     DOI: 10.1007/s11916-006-0029-8

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  18 in total

Review 1.  Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation).

Authors:  Terese T Horlocker; Denise J Wedel; Honorio Benzon; David L Brown; F Kayser Enneking; John A Heit; Michael F Mulroy; Richard W Rosenquist; John Rowlingson; Michael Tryba; Chun-Su Yuan
Journal:  Reg Anesth Pain Med       Date:  2003 May-Jun       Impact factor: 6.288

2.  Prevalence of symptoms among patients with advanced cancer: an international collaborative study. Symptom Prevalence Group.

Authors:  A Vainio; A Auvinen
Journal:  J Pain Symptom Manage       Date:  1996-07       Impact factor: 3.612

3.  Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology.

Authors:  T Meuser; C Pietruck; L Radbruch; P Stute; K A Lehmann; S Grond
Journal:  Pain       Date:  2001-09       Impact factor: 6.961

4.  Intrathecal drug delivery for the management of cancer pain: a multidisciplinary consensus of best clinical practices.

Authors:  Lisa Stearns; Richard Boortz-Marx; Stuart Du Pen; Gerhard Friehs; Michael Gordon; Michelle Halyard; Laurel Herbst; Jennifer Kiser
Journal:  J Support Oncol       Date:  2005 Nov-Dec

5.  Successful use of ketamine for intractable cancer pain.

Authors:  Dominique A Lossignol; Myriam Obiols-Portis; Jean-Jacques Body
Journal:  Support Care Cancer       Date:  2004-10-06       Impact factor: 3.603

6.  Chronic cannulation of the intradural or extradural space in the rat.

Authors:  M Bahar; M Rosen; M D Vickers
Journal:  Br J Anaesth       Date:  1984-04       Impact factor: 9.166

7.  Pain and its treatment in outpatients with metastatic cancer.

Authors:  C S Cleeland; R Gonin; A K Hatfield; J H Edmonson; R H Blum; J A Stewart; K J Pandya
Journal:  N Engl J Med       Date:  1994-03-03       Impact factor: 91.245

8.  Management of intrathecal catheter-tip inflammatory masses: a consensus statement.

Authors:  Samuel Hassenbusch; Kim Burchiel; Robert J Coffey; Michael J Cousins; Tim Deer; Marc B Hahn; Stuart Du Pen; Kenneth A Follett; Elliot Krames; James N Rogers; Oren Sagher; Peter S Staats; Mark Wallace; Kenneth Dean Willis
Journal:  Pain Med       Date:  2002-12       Impact factor: 3.750

9.  Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival.

Authors:  Thomas J Smith; Peter S Staats; Timothy Deer; Lisa J Stearns; Richard L Rauck; Richard L Boortz-Marx; Eric Buchser; Elena Català; David A Bryce; Patrick J Coyne; George E Pool
Journal:  J Clin Oncol       Date:  2002-10-01       Impact factor: 44.544

10.  Cost analysis of two implantable narcotic delivery systems.

Authors:  M D Bedder; K Burchiel; A Larson
Journal:  J Pain Symptom Manage       Date:  1991-08       Impact factor: 3.612

View more
  6 in total

Review 1.  Intrathecal Analgesia for Chronic Refractory Pain: Current and Future Prospects.

Authors:  Catherine Smyth; Nadera Ahmadzai; Jason Wentzell; Ashley Pardoe; Andrew Tse; Tiffany Nguyen; Yvette Goddard; Shona Nair; Patricia A Poulin; Becky Skidmore; Mohammed T Ansari
Journal:  Drugs       Date:  2015-11       Impact factor: 9.546

Review 2.  Intrathecal pumps.

Authors:  Shawn Belverud; Alon Mogilner; Michael Schulder
Journal:  Neurotherapeutics       Date:  2008-01       Impact factor: 7.620

Review 3.  Intrathecal analgesia for refractory cancer pain.

Authors:  Scott Newsome; Bridget K Frawley; Charles E Argoff
Journal:  Curr Pain Headache Rep       Date:  2008-08

4.  Intrathecal infusions for intractable cancer pain: a qualitative study of the impact on a case series of patients and caregivers.

Authors:  Philippa Hawley; Elizabeht Beddard-Huber; Cameron Grose; William McDonald; Daphne Lobb; Louise Malysh
Journal:  Pain Res Manag       Date:  2009 Sep-Oct       Impact factor: 3.037

Review 5.  Neuraxial pain relief for intractable cancer pain.

Authors:  Paul A Sloan
Journal:  Curr Pain Headache Rep       Date:  2007-08

6.  Intrathecal Morphine Infusion Therapy via a Percutaneous Port for Refractory Cancer Pain in China: An Efficacy, Safety and Cost Utilization Analysis.

Authors:  Wangjun Qin; Yifan Li; Botao Liu; Ying Liu; Yi Zhang; Xianglin Zhang; Pengmei Li; Bifa Fan
Journal:  J Pain Res       Date:  2020-01-23       Impact factor: 3.133

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.